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Oxidative modification of low-density lipoproteins and the out- Hyperlipidemia occurs in 40 to 80% of renal allograft
come of renal allografts at 11⁄2 years. recipients [1, 2]. Several clinical studies provide evidence
Background. Previous studies reported a significant associa- for an association between hypertriglyceridemia, low lev-
tion between hyperlipidemia of the recipient and chronic allo- els of high-density lipoprotein (HDL) cholesterol, and
graft nephropathy (CAN). However, the nature and the patho-
chronic allograft nephropathy (CAN) [3]. Strong circum-genic mechanism of circulating lipid abnormalities in CAN
stantial evidence substantiates that oxidized low-densityremain unclear.
lipoprotein (OxLDL) is more common in renal trans-Methods. In a prospective study of 50 consecutive adult re-
plant recipients than in normal individuals [4–6]. Thecipients of a cadaveric renal allograft, we investigated the im-
pact of lipid abnormalities on the outcome of the graft at 11⁄2 detrimental effects of OxLDL on glomerular and tubular
years. Besides morphometric analysis of implantation and proto- epithelial cells have been well documented in experimen-
col biopsies, clinical and biochemical variables were studied at tal studies [7–16] and could be prevented by dietary
three-month intervals. Plasma concentrations of oxidized low- antioxidants [17] and HDL [18].
density lipoprotein (OxLDL) were determined by means of Nevertheless, the exact role and the pathogenic mech-
enzyme-linked immunosorbent assay. Immunohistochemical anism of circulating lipid abnormalities and the contribu-staining for OxLDL and macrophages was performed on paired
tion of OxLDL to the development of CAN are currentlyrenal biopsies. Study end points were the fractional interstitial
unknown [19].volume and the 24-hour creatinine clearance at 11⁄2 years.
In a prospective clinicopathologic study in 50 consecutiveResults. High-density lipoprotein (HDL) cholesterol of the
adult recipients of a cadaveric renal allograft, under a cy-recipient #47 mg/dL was a risk factor for the functional (RR 5
1.56; 95% CI, 0.978 to 2.497) and the morphological (RR 5 closporine-based immunosuppressive regimen, we investi-
2.75; 95% CI, 1.075 to 7.037) outcome of the graft, mainly in gated the nature and the impact of lipid abnormalities on
patients without acute rejection (RR 5 2.03; 95% CI, 1.13 to the functional and morphological outcome of renal allo-
3.65, and RR 5 4.67; 95% CI, 1.172 to 18.582, respectively). grafts at 11⁄2-years post-transplantation. In addition, the roleInterstitial accumulation of OxLDL was inversely associated of oxidative modification and lipid peroxidation of LDL for
with HDL cholesterol (R 5 20.476, P 5 0.019), and was associ-
the development of CAN was assessed. Oxidative modifi-ated with a higher density of tubulointerstitial macrophages
cation of LDL may occur via mechanisms that are either(R 5 0.656, P 5 0.001) and a higher fractional interstitial
dependent or independent of lipid peroxidation: Malondi-volume at 11⁄2 years (P 5 0.049).
aldehyde-modified LDL is generated in the absence of lipidConclusion. Decreased HDL cholesterol levels of the recipi-
ent adversely affect the outcome of renal allografts through peroxidation, while oxidized LDL is generated by peroxi-
the accumulation of OxLDL in the renal interstitium of the dation of lipids in LDL [20]. Plasma concentrations of
graft. Interstitial accumulation of OxLDL was associated with malondialdehyde-modified and OxLDL were determined by
the presence of macrophages and the development of intersti- means of an enzyme-linked immunosorbent assay (ELISA),
tial fibrosis. while immunohistochemical staining for native, malondial-
dehyde-modified, and OxLDL was performed on implanta-
tion and protocol biopsies of the graft at 11⁄2 years.
Key words: oxidized LDL, kidney graft, transplantation, chronic allo-
graft nephropathy, high density lipoprotein, end-stage renal disease.
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tive study at our institution from January 1996 to Decem- Immunohistochemical staining for oxidatively
ber 1997. This study was approved by the local ethical modified LDL
committee. Informed consent was obtained from all pa- Additional implantation and protocol biopsy samples
tients. This study population, as well as the study design, were retrieved and snap frozen in liquid N2 within one
was previously described [21]. hour in OCT compound and were kept stored at 2858C
until processing. Six-micrometer sections were stainedStudy design
for native, malondialdehyde-modified, and oxidatively
In all patients, renal allograft biopsies were performed modified (OxLDL), by means of the avidin-biotin com-
at implantation—before reperfusion—with a 16G Tru- plex (ABC) method, with specific mouse monoclonal
Cutt Needle (Travenol, Baxter Healthcare Corp., Deer-
antibodies (L8A2, 1H11 [24], and Ox4E6 [25], respec-
field, IL, USA). Subsequent protocol biopsies at 18 months
tively). The sections were fixed for 20 minutes in 4%were similarly performed in 46 of these patients under
paraformaldehyde in phosphate-buffered saline. Aftercomputed tomography scan guidance. A protocol biopsy
rinsing with distilled water, the sections were washed forcould not be performed in four patients (8%): Three
five minutes in TSB (0.01 mol/L Tris-HCl, pH 7.4, inpatients were on anticoagulant therapy for imperative
0.9% NaCl) with 1% bovine serum albumin (BSA).cardiovascular indications, and a fourth patient returned
After 30 minutes of incubation with normal horse serumto dialysis because of chronic rejection. Clinical and bio-
1/5 in TSB/BSA, the sections incubated overnight atlogic data were prospectively registered in an MS-Access
room temperature with the respective antibodies (L8A2,7.0 database at implantation, 6 weeks, and 3, 6, 9, 12,
1/6000; 1H11, 1/8000; Ox4E6, 1/6000). Thereafter, en-15, and 18 months post-transplantation. The immunosup-
dogenous peroxidase activity was blocked by incubationpressive regimen was based on cyclosporine and predniso-
for 30 minutes in 0.03% H2O2 in TSB. In the next step,lone in all patients, but in 36 out of 50 (72%) patients,
the sections incubated for 30 minutes with HoAM 1/200either azathioprine or mycophenolate was added to the
in TSB/BSA and for one hour with ABC (Vector-kit,therapy at some time after transplantation. Antihyper-
Vectastrain, Vector Laboratories, Inc., Burlingame, CA,tensive drugs were used either in monotherapy (24% of
USA) in TSB/BSA. After washing with TSB/BSA andthe patients) or in combination treatment (76% of the
rinsing with distilled water, the sections incubated forpatients). Calcium channel inhibitors were the most fre-
quently used antihypertensives. five minutes with 0.02 mol/L Na-acetate (pH 5.1) and
subsequently for five minutes with amino ethyl carbazole
Morphology [(AEC) 20 mg AEC diluted in 24 mL dimethyl sulfoxide
All biopsies were fixed in Duboscq-Brazil and were (DMSO)], with an addition of 200 mL 0.02 mol/L AE
embedded in paraffin. Four micrometer sections were buffer (pH 5.1) and 4 mL 0.3% H2O2. After rinsing with
stained with hematoxylin and eosin, periodic acid-Schiff aq. dest., counterstaining was performed by incubation
(PAS), Masson trichrome. and silver methenamine. As- for three minutes with hemalun in aqueous solution.
sessment of specimen adequacy and histologic diagnosis Control staining, after omission of the primary anti-
were made by means of the Banff 97 criteria [22], in body, was performed on frozen sections of five renal
addition to the classic light microscopic histologic diag- transplant biopsies. Additional control staining with an
nosis and immunofluorescence studies for the detection unrelated primary antibody, that is, a mouse monoclonal
of immune deposits. The biopsy samples included a mean antibody directed against placental alkaline phosphatase
number of 13 glomeruli and 4 arteries per sample. (clone 7E8) [26], and staining after omission of the sec-
Additional morphometric analysis was performed on ondary horse anti-mouse antibody, was performed on
Masson trichrome-stained slides [21] and included the
frozen sections of six renal transplant biopsies.following: (1) the extent of glomerulosclerosis, expressed
The specificity of the immunohistochemical stainingas the proportion of obsolete glomeruli (percentage); (2)
for native, malondialdehyde (MDA)-modified, and OxLDLthe fractional interstitial volume, measured at a magnifi-
was assessed by means of preabsorption of each mono-cation of 3100 on all available cortical sections by means
clonal antibody with native, MDA-LDL, and OxLDL.of a Vidas 2.5 image analysis program and expressed as
Each immunostaining was performed on five renal trans-the proportion of the total cortical area consisting of
plant biopsies, as described previously in this article,interstitial space after deletion of glomeruli and arterial
before and after preincubation of L8A2, 1H11, andstructures; and (3) the ratio of arterial intima:media area
Ox4E6 with freshly prepared native LDL (13 mg/mL),and arterial vessel wall:total area of all cortical arteries.
MDA modified LDL (5 mg/mL), and OxLDL (9.4 andThis ratio was calculated from measurements on eight
18.8 mg/mL).orthogonal points of all cortical arteries by means of the
All sections were blinded to the reader and were sub-sector elliptic approach and was expressed as a percent-
sequently semiquantitatively scored at magnificationage [23]. Thirty-one adequate paired biopsies were avail-
able for this morphometric analysis. 25 3 10. Only biopsies including cortical material were
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analyzed. On each section, the arterial, glomerular, tubu- the number and time of occurrence of acute rejection
episodes (73% biopsy-proven, 27% clinically suspected),lar and interstitial compartments were separately scored
for immunostaining by means of the following criteria: the Banff score of acute rejections, and the weekly cyto-
megalovirus (CMV)-antigenemia (expressed as the num-0 5 no staining; 1 5 staining of less than 30% of the
area; 2 5 staining between 30 and 60% of the area; and ber of cells/200,000 leukocytes, detected by means of
immunofluorescence with a mouse monoclonal antibody3 5 staining more than 60% of the area. Because of
sampling limitations, 24 paired (implantation and proto- reacting with the CMV pp65 structural protein; Biosof,
Varilhes, France) for the first 12 postoperative weeks.col) cortical biopsies were available for this analysis.
Data retrieved once every three months included cyclo-
Immunohistochemical staining for macrophages sporine trough level (determined at 12 hours postintake
on whole blood samples with the TDx fluorescence polar-Immunostaining for macrophages was performed on
6 mm sections of cortical biopsies, after fixing in formol ization immunoassay, Abbott Laboratories, North Chi-
cago, IL, USA), serum creatinine level, 24-hour creati-calcium solution and embedding in paraffin. According
to the previously described ABC method, immunostain- nine clearance normalized for body surface area, 24-hour
proteinuria, body mass index, systolic and diastolic blooding was performed with a specific mouse monoclonal
antibody, directed against human CD68 (Clone PG-M1; pressure values, and determinations of plasma concen-
tration of total, HDL, LDL cholesterol, triglycerides,Dakot, Carpinteria, CA, USA), in addition to a nuclear
counterstaining with methyl green. All sections were apolipoprotein A1 and B, as well as the calculated value
of very low-density lipoprotein (VLDL) cholesterol.blinded to the reader. On each section, the number of
macrophages was determined on 10 consecutive fields The exposure of the recipient to CMV, the lipid and
lipoprotein fractions, and cyclosporine was derived fromat magnification (40 3 10), for the arterial, glomerular,
and tubulointerstitial compartments separately. Results the retrieved data by means of the summation of the
mean exposure at successive observation intervals. Theare expressed as the mean (6 SD) number of cells per
field. Because of sampling limitations, 21 paired (implan- calculation of the mean exposure was based on the trape-
zoidal rule, that is, the multiplication of the mean of twotation and protocol) cortical biopsies were available for
this analysis. consecutive measurements with the time interval (days).
Each exposure was normalized per day by dividing the
Determination of the plasma concentration of total exposure by the duration of observation (days).
malondialdehyde-modified and oxidized LDL
Study end pointsThe plasma concentration of malondialdehyde-modi-
fied and OxLDL was determined in the last-included 36 Two surrogate markers for long-term graft outcome
were used as end points for this study and were identicalpatients and 30 healthy controls (8 males and 22 females,
mean age of 36.1 6 4.75 years) who were recruited to the end points defined in a previous study [21]. Mor-
phological outcome was assessed by means of the frac-among the medical and nursing staff of the hospital.
At least one blood sample was withdrawn in a CTAD tional interstitial volume at 11⁄2 years, while functional
outcome was assessed by means of the 24-hour creatininetube (Beckton Dickinson, Mountain View, CA, USA)
and centrifuged for 20 minutes at 4500 r.p.m. at 48C after clearance (normalized for body surface area) at 11⁄2 years.
the addition of 50 mL of a solution, constituted of 7 mL
Statistical analysistri-Nacitrate, 1 mL vitamin E (117 mmol/L), and 2 mL
ethylenediaminetetraacetic acid (EDTA; 100 mg/mL). All data presented are expressed as mean (6 SD). The
following statistical tests were used where appropriate:After the addition of 10 mL solution, consisting of 100
mmol/L butylated hydroxytoluene in ethanol 3100 di- multivariate linear regression analysis (Table 2), the de-
termination of relative risk (Fig. 1), t test for independentluted in tri-Nacitrate (3.13%), 1 mL centrifuged plasma
was kept stored at 2858C in glass tubes until process- samples (Figs. 2, 6, and 7), the determination of the
Spearman correlation coefficient for categorical vari-ing. The plasma concentration of MDA-modified and
OxLDL was determined by means of an ELISA with ables (Tables 3–5), Wilcoxon’s test for paired samples
(Fig. 5), and the determination of the Pearson correlation1H11 and Ox4E6, respectively, as previously described
[24, 25]. coefficient for the association between the recipient’s
exposure to triglycerides and HDL cholesterol and
Clinical and biological data plasma OxLDL. Since the association between two bio-
logical variables may be related to the order of magni-Data retrieved at implantation were age and gender
of the donor, recipient age, cold ischemia time, and first tude of these variables, rather than to their individual
values, we divided into quartiles the continuous variablesand second warm ischemia time. Data retrieved post-
transplantation were delayed graft function (defined as HDL cholesterol (Table 3), density of interstitial macro-
phages (Tables 4 and 5), and fractional interstitial vol-the need for dialysis in the first postoperative week),
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Table 1. Demographic data and risk factors of the total study cohortume at 11⁄2 years (Table 5), and subsequently determined and the morphometrically studied patients
the nonparametric Spearman correlation coefficient.
Total study MorphometricallyThe predictive value of donor-related and post-trans-
cohort studied patients
plant risk factors was determined in multivariate linear (N 5 50) (N 5 31)
regression analysis of the dependent variables, that is, Donor age years 41616 43617
Recipient age years 48614 49612the fractional interstitial volume and the creatinine clear-
Sex of donor male/female 31/19 18/13ance at 11⁄2 years. Variables tested in the predictive model Cold ischemia time hours 2065 2066
were donor age, glomerulosclerosis at implantation, the 2nd ischemia time minutes 3169 3069
Delayed graft function N (%) 16/50 (32%) 9/31 (29%)fractional interstitial volume at implantation, the loga-
Acute rejection
rithmic transformed value of the ratio of arterial in- Clinically suspected N (%) 3/50 (6%) 2/31 (6.5%)
Banff 1 N (%) 4/50 (8%) 2/31 (6.5%)tima:media area and arterial wall:total area at implanta-
Banff 2 N (%) 7/50 (14%) 4/31 (13%)tion, as well as the cold ischemia time, the number and CMV infection N (%) 20/50 (40%) 14/31 (45%)
the Banff grade of acute rejection episodes, the protein- Cyclosporine dose exposure
mg/kg 3.561.5 3.461.1uria and the mean blood pressure of the recipient, the
Cyclosporine trough level
mean exposure of the recipient to triglycerides, HDL exposure ng/mL 164657 165655
Mean arterial blood pressureand LDL cholesterol, the mean exposure of the recipient
mm Hg 10166 10266to cyclosporine dose and trough level, and CMV infec- Proteinuria mg/24 h 4506872 3466631
tion. Goodness-of-fit of the predictive model was as- Recipient’s exposure to total
cholesterol mg/dL 221646.7 226631.2sessed by means of R square, the coefficient of determi-
Recipient’s exposure to HDL
nation. The predictive model yielding the highest R2 for cholesterol mg/dL 53.7617 49.4612
Recipient’s exposure tothe multivariate regression analysis of both dependent
triglycerides mg/dL 172672 185665variables was selected as the best fitting model. Regres- Creatinine clearance at 11⁄2
years mL/min 62618 61615sion analysis for the fractional interstitial volume at 11⁄2
Data are mean 6 SD or number (%). Abbreviations are: CMV, cytomegalovi-years was performed on all cases with adequate implanta-
rus; HDL, high-density lipoprotein.tion and protocol biopsies (N 5 31). Regression analysis
for the creatinine clearance at 11⁄2 years was performed
on all cases with adequate implantation biopsies (N 5 41).
The relative risk for interstitial fibrosis or decreased ble 1), it can be assumed that the latter subpopulation
renal function at 11⁄2 years was calculated as the ratio of is representative for the whole study cohort.
In a multivariate regression analysis, the occurrencethe incidences of the adverse outcome in the group at
of an acute rejection episode, logarithmic-transformedrisk and the group not at risk. Interstitial fibrosis was
value of the ratio of arterial intima/media area at implan-defined as the fractional interstitial volume above 30%
tation, exposure of the recipient to HDL cholesterol,(50th percentile of the fractional interstitial volume at
and diastolic blood pressure substantially predicted the11⁄2 years). Decreased renal function was defined as the
fractional interstitial volume (R2 5 0.314, P 5 0.028) andmeasured creatinine clearance below 64 mL/min (50th
the creatinine clearance (R2 5 0.310, P 5 0.006) at 11⁄2percentile of the creatinine clearance at 11⁄2 years). The
years (Table 2).cut-off value for the risk factor was defined as the 50th
The relative risk of the recipient’s exposure to HDLpercentile of the mean exposure of the recipient to HDL
cholesterol #47 mg/dL was 2.75 (95% CI, 1.075 to 7.037)cholesterol, that is, 47 mg/dL, and the 50th percentile of
for interstitial fibrosis and 1.56 (95% CI, 0.978 to 2.497)
the mean exposure of the recipient to triglycerides, that
for decreased renal function at 11⁄2 years (Fig. 1A). Theis, 168 mg/dL. The relative risk for interstitial fibrosis relative risk of the recipient’s exposure to triglycerides
was determined on all cases with adequate protocol biop-
$168 mg/dL was 2.26 (95% CI, 0.778 to 6.570) for inter-
sies (N 5 36), while the relative risk for decreased renal stitial fibrosis and 1.66 (95% CI, 1.018 to 2.700) for de-
function was calculated on all cases with available creati- creased renal function at 11⁄2 years (Fig. 1B). Since the
nine clearance at 11⁄2 years (N 5 49). All tests were occurrence of at least one acute rejection episode ad-
performed with SPSS 9.0. versely affected the fractional interstitial volume (FIV)
at 11⁄2 years (36.6 6 13.4% vs. 29.0 6 5.8%, P 5 0.036;
Fig. 2), the impact of the recipient’s exposure to HDL
RESULTS cholesterol and triglycerides was re-evaluated in patients
Since the demographic data and risk factors were not without any acute rejection episode.
statistically different in the total study cohort (N 5 50) In patients without an acute rejection episode(s), the
relative risk of the recipient’s exposure to HDL choles-and the morphometrically studied patients (N 5 31; Ta-
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Table 2. Multivariate linear regression models of the fractional interstitial volume (FIV) and creatinine clearance at 11⁄2 years
A. FIV in protocol biopsies (R2 5 0.314, P 5 0.028) B. Creatinine clearance (R2 5 0.310), P 5 0.006)
Selected covariates Coefficient SE Beta 95% CI Coefficient SE Beta 95% CI
Acute rejection number 1.914 1.684 10.188 21.536–5.365 5.012 4.253 10.172 23.598–13.621
Log intima:media area 18.602 8.354 10.356 1.489–35.716 238.821 18.897 20.285 277.075–20.566
HDL exposure mg/dL/day 20.09654 0.066 20.246 20.232–0.039 0.560 0.161 10.531 0.235–0.885
Diastolic blood pressure mm Hg 0.104 0.172 10.099 20.249–0.457 0.692 0.367 10.273 20.051–1.436
The magnitudes of the standardized beta coefficients indicate the relative strength of the association of, respectively, FIV (A) and creatinine clearance (B) with
the respective baseline covariates. Abbreviations are: HDL, high density lipoprotein; SE, standard error; CI, confidence interval.
a Logarithm transformation applied to the ratio of arterial intima:media area in implantation biopsies
Fig. 1. Relative risk and 95% CI of the recipient’s exposure to high-density lipoprotein (HDL) cholesterol #47 mg/dL (A) and triglycerides $168
mg/dL (B) for the development of interstitial fibrosis (FIV .30%) or decreased renal function (creatinine clearance ,64 mL/min) at 11⁄2 years in
all recipients and in recipients without acute rejection.
terol #47 mg/dL was 4.67 (95% CI, 1.172 to 18.582) for
interstitial fibrosis and 2.03 (95% CI, 1.130 to 3.650)
for decreased renal function at 11⁄2 years (Fig. 1A). The
relative risk of the recipient’s exposure to triglycerides
$168 mg/dL was 5.18 (95% CI, 0.747 to 35.863) for
interstitial fibrosis and 2.5 (95% CI, 1.26 to 4.96) for
decreased renal function at 11⁄2 years in patients without
an acute rejection episode(s) (Fig. 1B).
Immunohistochemical expression of L8A2 (specific
for native LDL) and of Ox4E6 (specific for oxidized LDL)
was clearly observed in four and, respectively, three out
of the five biopsies used for the specificity assessment.
Immunostaining of glomeruli, arteries, and interstitium
for native and OxLDL cholesterol was specific. Indeed,
the expression of L8A2 (Fig. 3A) was completely inhibited
after preincubation with native LDL (Fig. 3B) in four out
of four biopsies, and the expression of Ox4E6 (Fig. 3C)
was completely inhibited after preincubation with OxLDL
(Fig. 3D) in three out of three of the biopsies. Since
the immunostaining for malondialdehyde-modified LDL
Fig. 2. Fractional interstitial volume (mean 6 SD) in protocol biopsies was absent in three out of five biopsies and was onlyof recipients without (2) and with at least one acute rejection episode
(1) (**P 5 0.036). weakly positive in glomeruli and arteries in two remaining
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Fig. 3. Immunohistochemical expression of
L8A2 and Ox4E6 before (A, L8A2; C, Ox4E6)
and after preincubation with a competitive
antigen (B, L8A2 1 LDL; D, Ox4E6 1
OxLDL) at a magnification of 3250. Glomer-
ular, arterial, and interstitial immunostaining
was inhibited after preincubation of L8A2
with native LDL (B vs. A) and after preincu-
bation of Ox4E6 with OxLDL (D vs. C). Note
the unspecific staining of tubuli in B and D
(arrows), persisting after preincubation of the
primary antibodies with the competitive an-
tigen.
Fig. 4. Immunohistochemical expression of
Ox4E6 in a renal allograft at 11⁄2 years (A) at
a magnification of 3250. Glomerular staining
for OxLDL shows a mesangiocapillary pattern
(B, magnification 3400). In arteries, immuno-
staining for OxLDL is mainly observed in en-
dothelial cells and in isolated cells in the arte-
rial wall (arrows; C, magnification 3800).
Interstitial immunostaining for OxLDL is
more diffuse (A and D, magnification 3400).
biopsies, no valid conclusions could be drawn about the LDL and OxLDL was observed in the renal interstitium
(Fig. 4 A, D).specificity of this staining, after preincubation of 1H11
with malondialdehyde modified LDL. Moreover, the im- Although immunostaining for LDL and OxLDL was
already positive in some implantation biopsies (Fig. 5), amunohistochemical staining for native and OxLDL was
nonspecific in tubuli, since a positive staining of the tubuli significantly increased immunostaining of the interstitial
compartment could be observed for both native andwas also observed in control stainings without a primary
or secondary antibody or with an unrelated primary anti- OxLDL in protocol biopsies compared with implantation
biopsies (P 5 0.003 and P 5 0.004, respectively, Wil-body (data not shown). Tubular immunostaining for na-
tive and OxLDL was not inhibited after preincubation coxon’s signed rank test; Fig. 5). In addition, immuno-
staining for OxLDL was also increased in glomeruli ofwith the respective antigens (Figs. 3 B, D).
Glomerular immunostaining for LDL and OxLDL was protocol biopsies versus implantation biopsies (P 5
0.002, Wilcoxon’s signed rank test; Fig. 5).observed in a mesangiocapillary pattern (Fig. 4B). In
arteries, endothelial cells and isolated cells in the arterial Accumulation of OxLDL, that is, an increase of the
semiquantitative score in protocol versus implantationintima and media stained positive for LDL and OxLDL
(Fig. 4C). In contrast, a more diffuse immunostaining for biopsies, was observed in the renal interstitium of 15 out
Bosmans et al: OxLDL and renal allograft outcome2352
Fig. 6. Fractional interstitial volume at 11⁄2 years in grafts with stable
or decreased (2) interstitial expression and grafts with increased (1)
interstitial expression of OxLDL (mean 6 SD) in protocol biopsies
versus implantation biopsies (*P 5 0.049).
Table 3. Inverse correlation between the recipient’s exposure to
HDL cholesterol (divided into quartiles), and the increase
(positive values) or decrease (negative values) of the
interstitial semiquantitative score of oxidized LDL
in protocol vs. implantation biopsies
Interstitial accumulation
of OxLDL
Quartile 22 21 0 1 2 3 Total
HDL cholesterol mg/dL ,42 1 4 1 6
$42–,47 1 2 2 1 6
$47–,64 2 1 3 6
$64 1 1 2 1 1 6
Total 1 2 6 5 9 1 24
Data are by the Spearman correlation: R 5 20.476; P 5 0.019; N 5 24.
Fig. 5. Semiquantitative score of the immunohistochemical expression
of Ox4E6 (A) and L8A2 (B) in the arterial, glomerular, and interstitial
compartment of 24 paired implantation ( ) and protocol (j) biopsies. Table 4. Correlation between the increase (positive values) or the
Data are mean 6 SD; **P , 0.01. The semiquantitative scores are: 0 5 decrease (negative values) of the interstitial semiquantitative score
no staining; 1 5 ,30%; 2 5 30 to 60%; and 3 5 . 60% staining of of OxLDL in protocol versus implantation biopsies, and the density
the area. of tubulointerstitial macrophages (divided into quartiles) at 11⁄2 years
Interstitial accumulation
of OxLDL
Quartile 22 21 0 1 2 3 Totalof 24 paired biopsies and was associated with a higher
Density of interstitialFIV (35.45 6 9.9 vs. 27.33 6 7.8%, P 5 0.049; Fig. 6).
macrophages cells/field ,2 1 1 1 2 5The accumulation of oxidized LDL in the renal intersti- $2–,7 1 1 2 1 5
tium was inversely associated with the recipient’s expo- $7–,12 2 4 6
$12 1 3 1 5sure to HDL cholesterol (R 5 20.476, P 5 0.019, Spear-
Total 1 2 4 5 8 1 21
man correlation; Table 3). The recipient’s exposure to
Data are by the Spearman correlation: R 5 0.656; P 5 0.001; N 5 21.
triglycerides tended to be associated with accumulation
of OxLDL in the renal interstitium, although this trend
was not significant (R 5 0.336, P 5 0.105, Spearman
correlation). ment of renal biopsies at 11⁄2 years (R 5 0.656, P 5 0.001,
Moreover, the accumulation of OxLDL in the renal Spearman correlation; Table 4).
interstitium was associated with a significantly higher Furthermore, the density of macrophages in the tubu-
lointerstitial compartment was significantly associateddensity of macrophages in the tubulointerstitial compart-
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Table 5. Correlation between the fractional interstitial volume (divided into quartiles) and the density of tubulointerstitial macrophages
(divided into quartiles) in protocol biopsies at 11⁄2 years
Fractional interstitial volume %
Quartile ,27% $27%–,33% $33%–,37% $37% Total
Density of interstitial macrophages cells/field ,2 2 1 2 5
$2–,7 2 2 1 5
$7–,12 2 2 1 1 6
$12 1 4 5
Total 6 6 4 5 21
Data are by the Spearman correlation: R 5 0.481; P 5 0.027; N 5 21.
and CAN [27, 28], while others reported a significant
correlation between decreased HDL cholesterol, in-
creased triglycerides, and CAN [29]. Equally controver-
sial is whether dyslipidemia plays a causative role in the
development of CAN or is merely an epiphenomenon
of CAN [30]. In this regard, prospective randomized,
controlled studies analyzing the impact of lipid-lowering
drugs on the development of CAN are presently lacking.
Finally, although a causative role of the oxidatively modi-
fied LDL for the progression of renal disease has been
suggested [7, 31], the pathophysiologic mechanism by
which hyperlipidemia of the recipient could induce the
development of CAN is still not elucidated.
Despite the small number of patients included in this
study, the prospective design with the inclusion of all
known risk factors for graft failure and combination of
Fig. 7. Plasma concentration of OxLDL in healthy controls and trans- morphological and functional end points enabled us to
plant recipients (mean 6 SD). ***P , 0.001. evaluate the role of hyperlipidemia in the genesis of CAN.
To our knowledge, this is the first prospective study in
renal transplant recipients with a documented morpho-
metric analysis of baseline and protocol biopsies, as wellwith the extent of interstitial fibrosis at 11⁄2 years (R 5
as documented exposure to a variety of risk factors.0.481, P 5 0.027, Spearman correlation; Table 5).
In this prospective clinicopathologic study, exposureThe plasma concentration of OxLDL was significantly
of the recipient to HDL cholesterol levels below 47 mg/dLhigher in transplant recipients compared with healthy
during the first 18 months post-transplantation was ancontrols (1.58 6 1.50 vs. 0.31 6 0.16 mg/dL, P , 0.001;
independent predictor for the development of interstitialFig. 7).
fibrosis and reduced renal function at 11⁄2 years in multi-The plasma levels of OxLDL correlated with the recip-
variate regression analysis. This risk was even more pro-ient’s exposure to triglycerides (R 5 0.574, P , 0.001,
nounced in patients who did not sustain any acute rejec-Pearson correlation) and were inversely associated with
tion episode. Since the detrimental effect of an acuteHDL exposure (R 5 20.347, P 5 0.038, Pearson correla-
rejection episode on graft outcome has been repeatedlytion). However, no correlation could be demonstrated
documented [32–34] and was recently confirmed in abetween the plasma concentration of malondialdehyde-
large survey [35], as well as in our predictive model, themodified or OxLDL and the accumulation of OxLDL
occurrence of an acute rejection episode is a major riskin the renal interstitium.
factor for graft outcome. However, according to our data,
exposure of the recipient to lower HDL cholesterol lev-
DISCUSSION els is also a risk factor for graft outcome, particularly in
patients who did not experience the adverse effects ofWhile several previous studies highlighted a significant
association between hyperlipidemia of the recipient and an acute rejection episode.
Moreover, exposure of the recipient to triglyceridesthe development of CAN, many questions remain un-
solved. A primary controversy is the exact nature of above 168 mg/dL also represented an increased risk for
adverse graft outcome. These data are in line with previ-the dyslipidemia associated with CAN [3]. Indeed, some
authors found an association between LDL cholesterol ous studies [28, 29]. In contrast with others [27, 28],
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however, we were unable to demonstrate any association Interstitial immunostaining for OxLDL was increased
in 15 out of 24 protocol biopsies compared with implanta-between total, LDL, VLDL cholesterol exposure, and
subsequent graft outcome. tion biopsies in our study. This interstitial accumulation
of OxLDL inversely correlated with the exposure of theAlthough a significant association does not necessarily
imply a causal relationship, some arguments favor the recipient to HDL cholesterol and showed a trend for
association with the recipient’s exposure to triglycerides.hypothesis that low HDL levels and hypertriglyceride-
mia of the recipient may adversely affect the subsequent Increased plasma levels of triglyceride and decreased
levels of HDL cholesterol have been consistently corre-graft outcome. In our prospective study, the morphologic
and functional alterations were preceded by the expo- lated with the presence of small dense LDL, indicated
as the LDL subclass pattern B [54, 55]. Ghanem et alsure. Observations in primary renal diseases reported a
similar association between elevated triglycerides [36, 37] found an increased prevalence of small dense LDL in
renal transplant recipients that was associated with aor lower HDL cholesterol [38] and the subsequent pro-
gression of renal disease. In a recent large study in 12,728 higher plasma triglyceride and a lower HDL cholesterol
level [4]. This LDL subclass pattern B exhibited an in-participants of the Atherosclerosis Risk in Communities
Study, with baseline serum creatinine less than 2 mg/dL, creased susceptibility to oxidative modification in vitro
[4]. Similarly, Sutherland et al showed an increased sus-low HDL cholesterol and elevated triglycerides were
independent risk factors for the subsequent decline in ceptibility for oxidation of triglyceride-rich LDL in fe-
male renal transplant recipients [5]. In view of theserenal function [39]. Moreover, experimental studies in
the analbuminemic rat demonstrated the protective role data, the documented exposure of the recipient to lower
HDL cholesterol and elevated triglycerides in our studyof the reduction of triglycerides, for the subsequent de-
velopment of glomerulosclerosis and proteinuria [40]. potentially reflects the presence of small dense LDL.
Since small dense LDL is more prone to oxidative modi-Finally, in heart transplant recipients, HDL cholesterol
was the only lipid parameter significantly and inversely fication than larger LDL [56, 57], the presence of small
dense LDL could have contributed to the interstitialassociated with the occurrence of new major coronary
events [41], while OxLDL predicted transplant-associ- accumulation of OxLDL in recipients with lower HDL
cholesterol and elevated triglyceride levels.ated coronary artery disease [42].
How could exposure of the recipient to low levels of The density of macrophages in the tubulointerstitial
compartment was significantly higher in renal allograftsHDL cholesterol and elevated triglycerides contribute
to the deterioration of the renal allograft? Experimental with interstitial accumulation of oxidized LDL at 11⁄2
years and was associated with the extent of interstitialand human studies strongly suggest that many biochemi-
cal and histologic features that accompany glomerulo- fibrosis at 11⁄2 years. Several studies have demonstrated
the chemotactic capacity of modified LDL for monocytessclerosis are similar to those observed in the systemic
vascular lesions of atherosclerosis [32]. The promoting and macrophages, not only at the arterial level [58–60],
but also in glomeruli [10–12].role of oxidatively modified LDL in the formation of the
arteriosclerotic lesion has been well documented [43, 44]. The fibrogenic role of macrophages in glomeruloscle-
rosis [61] and interstitial fibrosis has been well describedSeveral animal and in vitro experiments have similarly
highlighted the effects of oxidatively modified LDL on [62]. According to current insights, macrophages release
tissue inhibitor of metalloproteinase-1 (TIMP-1), a prote-glomerular and tubular epithelial cells [7–16], as well as
the protective effects of dietary antioxidant [17], probu- ase inhibitor [62–64], as well as fibrosis-promoting cyto-
kines, such as transforming growth factor-b1 (TGF-b) [63].col [45], and HDL [18]. Two distinct mechanisms could
contribute to the protective role of HDL in the formation Although the plasma concentration of OxLDL in trans-
plant recipients was significantly higher than in healthyof OxLDL [46–49]. Paraoxonase 1 [50] and platelet-acti-
vating factor acetylhydrolase [51], two HDL-associated controls and was inversely correlated with HDL expo-
sure, we were unable to demonstrate any correlationenzymes, have been shown to inhibit LDL lipid peroxida-
tion in vitro. In addition, HDL could act as a reservoir between this parameter and the accumulation of OxLDL
in the renal interstitium. This observation suggests thatfor lipid peroxides generated on LDL [46], thereby en-
hancing the hepatic uptake and catabolism of oxidized the oxidative modification of LDL could occur in situ in
the renal parenchyma and is less likely to result from thecholesteryl esters [52].
In the present study, immunostaining for LDL and deposition of circulating OxLDL. Similar observations
were made in an experimental model in normotensiveOxLDL in renal allografts was observed in a mesangio-
capillary pattern in glomeruli, in vascular endothelial obese rats [65].
In conclusion, decreased HDL cholesterol levels ofcells, and in the interstitial space. Interestingly, a similar
distribution pattern of LOX-1, an OxLDL receptor, was the recipient adversely affect the morphologic and func-
tional outcome of cadaveric renal allografts. Our datarecently demonstrated in renal cortical tissue of Dahl
salt-sensitive rats [53]. provide evidence that this may be due to accumulation
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